theMednet - For patients who develop pneumonitis (radiation vs. TKI induced) while on Pralsetinib for RET-rearranged metastatic NSCLC, is there a role to switch to another agent (i.e. Selpercatinib)?

Topics: Lung Cancer • Thoracic Malignancies • Medical Oncology • NCI-CCC Tumor Board Question • Indiana University • RET+ • NCI-CCC Thoracic Tumor Board Question

For patients who develop pneumonitis (radiation vs. TKI induced) while on Pralsetinib for RET-rearranged metastatic NSCLC, is there a role to switch to another agent (i.e. Selpercatinib)?